Century Therapeutics (IPSC) Shares Outstanding (Diluted Average) (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $193.5 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $193.5 million, up 124.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.5 million (up 124.71% YoY), and the FY2025 annual result was $86.6 million, up 10.05% from the prior year.
• Shares Outstanding (Diluted Average) grew to $193.5 million in Q1 2026 per IPSC's latest filing, from $86.6 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $193.5 million in Q1 2026 and troughed at $32.4 million in Q4 2022.
• A 5-year average of $74.7 million and a median of $62.3 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 643.13% in 2022 and fell as far as 0.0% in 2022.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $32.4 million in 2022, then jumped by 83.11% to $59.3 million in 2023, then surged by 32.6% to $78.6 million in 2024, then grew by 10.05% to $86.6 million in 2025, then surged by 123.52% to $193.5 million in 2026.
• Business Quant data shows IPSC's Shares Outstanding (Diluted Average) at $193.5 million in Q1 2026, $86.6 million in Q4 2025, and $86.4 million in Q3 2025.